In two phase 3 studies ( AMAGINE-2 and AMAGINE-3 ) , patients with moderate-to-severe psoriasis were randomly assigned to receive brodalumab ( 210 mg or 140 mg every 2 weeks ) , ustekinumab ( 45 mg for patients with a body weight 100 kg and 90 mg for patients > 100 kg ) , or placebo .